T1	Person 3 8	Women
T2	Condition 17 25	pregnant
T3	Observation 33 42	lactating
*	OR T2 T3
T4	Person 47 52	women
T5	Observation 57 75	intend to conceive
T6	Temporal 76 89	within a year
R1	Has_temporal Arg1:T5 Arg2:T6	
T7	Scope 47 89	women who intend to conceive within a year
T8	Scope 3 42	Women who are pregnant and/or lactating
*	OR T8 T7
T9	Observation 95 102	History
T10	Condition 106 115	allergies
T11	Drug 119 128	enalapril
T12	Drug 130 140	folic acid
T13	Drug 150 181	components of the compound drug
*	OR T12 T13 T11
T14	Scope 119 181	enalapril, folic acid or other components of the compound drug
R2	Has_scope Arg1:T10 Arg2:T14	
R3	Has_temporal Arg1:T10 Arg2:T9	
T15	Observation 187 194	History
T16	Condition 198 215	adverse reactions
T17	Condition 219 230	intolerance
T18	Drug 234 243	enalapril
T19	Qualifier 247 252	other
T20	Drug 253 267	ACE inhibitors
T21	Drug 304 314	folic acid
R4	Has_qualifier Arg1:T20 Arg2:T19	
*	OR T18 T20 T21
*	OR T17 T16
T22	Scope 198 230	adverse reactions or intolerance
T23	Scope 234 314	enalapril or other ACE inhibitors, or drugs or supplements containing folic acid
R5	Has_scope Arg1:T22 Arg2:T23	
R6	Has_temporal Arg1:T22 Arg2:T15	
T24	Condition 346 368	secondary hypertension
T25	Mood 333 342	suspicion
T26	Mood 320 329	Diagnosis
*	OR T26 T25
T27	Scope 320 342	Diagnosis or suspicion
R7	Has_scope Arg1:T24 Arg2:T27	
T28	Qualifier 380 387	serious
T29	Condition 388 406	medical conditions
R8	Has_qualifier Arg1:T29 Arg2:T28	
T31	Condition 470 489	cardiac dysfunction
T32	Qualifier 449 469	clinically diagnosed
T33	Measurement 491 501	NYHA class
T34	Value 502 515	III and above
R9	Has_value Arg1:T33 Arg2:T34	
R10	Has_qualifier Arg1:T31 Arg2:T32	
T35	Scope 491 515	NYHA class III and above
R11	Subsumes Arg1:T31 Arg2:T35	
T36	Condition 518 557	hypertrophic obstructive cardiomyopathy
T30	Qualifier 559 581	clinically significant
T37	Condition 582 604	valvular heart disease
T38	Condition 606 629	acute coronary syndrome
T39	Temporal 630 654	within the last 3 months
R12	Has_temporal Arg1:T38 Arg2:T39	
T40	Procedure 659 699	percutaneous coronary intervention (PCI)
T41	Procedure 704 739	coronary artery bypass graft (CABG)
T42	Value 744 752	abnormal
T43	Temporal 753 767	pre-enrollment
T44	Measurement 768 776	ECG test
R13	Has_value Arg1:T44 Arg2:T42	
R14	Has_temporal Arg1:T44 Arg2:T43	
T45	Qualifier 790 812	clinically significant
T46	Condition 813 824	arrhythmias
T47	Condition 826 840	atrial flutter
T48	Condition 842 861	atrial fibrillation
T49	Condition 876 898	atrioventricular block
T50	Qualifier 863 871	grade II
T51	Qualifier 863 868;872 875	grade III
*	OR T51 T50
T52	Scope 863 875	grade II-III
R15	Has_scope Arg1:T49 Arg2:T52	
*	OR T47 T48 T49
T53	Scope 826 898	atrial flutter, atrial fibrillation, grade II-III atrioventricular block
R16	Has_qualifier Arg1:T46 Arg2:T45	
T54	Scope 790 824	clinically significant arrhythmias
R17	Subsumes Arg1:T54 Arg2:T53	
T55	Temporal 920 928	previous
T56	Condition 959 974	viral hepatitis
T57	Qualifier 997 1009	active phase
R18	Has_qualifier Arg1:T56 Arg2:T57	
T58	Value 1011 1019	abnormal
T59	Measurement 1035 1054	liver function test
R19	Has_value Arg1:T59 Arg2:T58	
T60	Temporal 1020 1034	pre-enrollment
T61	Measurement 1064 1067	ALT
T62	Measurement 1069 1072	AST
T63	Measurement 1074 1077	GGT
T64	Measurement 1079 1083	TBIL
T65	Measurement 1088 1092	DBIL
T66	Value 1093 1119	3 times higher than normal
*	OR T61 T62 T63 T64 T65
T67	Scope 1064 1092	ALT, AST, GGT, TBIL, or DBIL
R20	Has_value Arg1:T67 Arg2:T66	
T68	Measurement 1121 1124	ALB
T69	Value 1125 1132	= 30g/L
R21	Has_value Arg1:T68 Arg2:T69	
R22	Has_temporal Arg1:T59 Arg2:T60	
T70	Procedure 1135 1146	gastrectomy
T71	Procedure 1154 1171	gastrojejunostomy
T72	Condition 1173 1201	gastrointestinal dysfunction
T73	Temporal 1212 1226	pre-enrollment
T74	Measurement 1227 1243	serum creatinine
T75	Value 1244 1266	greater than 200umol/L
R23	Has_value Arg1:T74 Arg2:T75	
R24	Has_temporal Arg1:T74 Arg2:T73	
T76	Qualifier 1268 1286	clinical diagnosis
T77	Condition 1290 1311	renal artery stenosis
R25	Has_qualifier Arg1:T77 Arg2:T76	
T78	Procedure 1330 1352	kidney transplantation
T79	Condition 1313 1328	isolated kidney
T80	Condition 1387 1402	type 1 diabetes
T81	Qualifier 1406 1418	uncontrolled
T82	Condition 1419 1434	type 2 diabetes
T83	Measurement 1436 1457	fasting blood glucose
T84	Value 1458 1475	above 11.1 mmol/L
T85	Temporal 1476 1493	at pre-enrollment
R26	Has_value Arg1:T83 Arg2:T84	
R27	Has_temporal Arg1:T83 Arg2:T85	
T86	Reference_point 1479 1493	pre-enrollment
R28	Has_index Arg1:T85 Arg2:T86	
R29	Has_qualifier Arg1:T82 Arg2:T81	
T87	Scope 1436 1493	fasting blood glucose above 11.1 mmol/L at pre-enrollment
T88	Scope 1406 1434	uncontrolled type 2 diabetes
R30	Subsumes Arg1:T88 Arg2:T87	
T89	Temporal 1496 1504	previous
T90	Condition 1518 1533	hyperthyroidism
T91	Observation 1538 1556	failure to correct
R31	Has_context Arg1:T90 Arg2:T91	
R32	Has_temporal Arg1:T90 Arg2:T89	
T92	Condition 1571 1594	pulmonary heart disease
T93	Condition 1596 1633	chronic obstructive pulmonary disease
T94	Temporal 1653 1659	recent
T95	Condition 1660 1685	transient ischemic attack
T96	Condition 1689 1695	stroke
*	OR T96 T95
T97	Temporal 1697 1721	within the last 3 months
T98	Scope 1660 1695	transient ischemic attack or stroke
R33	Has_temporal Arg1:T98 Arg2:T97	
T99	Qualifier 1724 1734	peripheral
T100	Qualifier 1738 1744	severe
T101	Condition 1745 1766	autonomic dysfunction
*	OR T100 T99
T102	Scope 1724 1744	peripheral or severe
R34	Has_scope Arg1:T101 Arg2:T102	
T103	Condition 1768 1774;1786 1804	mental system dysfunction
T104	Condition 1778 1804	nervous system dysfunction
R35	Subsumes Arg1:T97 Arg2:T94	
T105	Scope 1064 1132	ALT, AST, GGT, TBIL, or DBIL 3 times higher than normal, ALB = 30g/L
R36	Subsumes Arg1:T59 Arg2:T105	
R37	Has_temporal Arg1:T56 Arg2:T55	
*	OR T31 T36 T37 T38 T40 T41 T44
R38	Has_qualifier Arg1:T37 Arg2:T30	
R39	Has_scope Arg1:T44 Arg2:T54	
T106	Observation 1806 1833	inability to express desire
T107	Condition 1841 1845;1857 1867	drug dependence
T108	Condition 1849 1867	alcohol dependence
*	OR T108 T107 T109 T110 T111 T56 T59 T92 T93 T98 T103 T104 T101 T90 T80 T88 T79 T78 T77 T74 T72 T71 T70 T54 T106
T109	Condition 1869 1879	Malignancy
T110	Condition 1881 1893	malnutrition
T111	Condition 1895 1918	hematopoietic disorders
T112	Scope 449 1918	clinically diagnosed cardiac dysfunction (NYHA class III and above), hypertrophic obstructive cardiomyopathy, clinically significant valvular heart disease, acute coronary syndrome within the last 3 months, or percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG); or abnormal pre-enrollment ECG test results with clinically significant arrhythmias (atrial flutter, atrial fibrillation, grade II-III atrioventricular block, etc.); Digestive: a previous diagnosis of various types of viral hepatitis that are still in the active phase; abnormal pre-enrollment liver function test results (ALT, AST, GGT, TBIL, or DBIL 3 times higher than normal, ALB = 30g/L); gastrectomy and/or gastrojejunostomy; gastrointestinal dysfunction; Urinary: pre-enrollment serum creatinine greater than 200umol/L; clinical diagnosis of renal artery stenosis, isolated kidney, kidney transplantation and/or other diseases; Endocrine: type 1 diabetes or uncontrolled type 2 diabetes (fasting blood glucose above 11.1 mmol/L at pre-enrollment); previous diagnosis of hyperthyroidism and failure to correct; Respiratory: pulmonary heart disease; chronic obstructive pulmonary disease; Neuropsychiatric: recent transient ischemic attack or stroke (within the last 3 months); peripheral or severe autonomic dysfunction; mental or nervous system dysfunction, inability to express desire; known drug or alcohol dependence; Malignancy, malnutrition, hematopoietic disorders
R40	Subsumes Arg1:T29 Arg2:T112	
T113	Qualifier 1951 1962	Significant
T114	Condition 1963 1985	signs of abnormalities
T115	Measurement 1997 2013	laboratory tests
R41	AND Arg1:T115 Arg2:T114	
R42	Has_qualifier Arg1:T114 Arg2:T113	
T116	Non-representable 2014 2305	or physical characteristics, which, at the discretion of the investigators, indicates that the patient is experiencing a serious illness or, may affect the observation and evaluation of the drug's efficacy or adverse events, or renders the patient unsuitable for participating in this study;
T117	Drug 2336 2342	folate
T118	Drug 2344 2347	B12
T119	Drug 2352 2354	B6
*	OR T117 T118 T119
T120	Observation 2420 2441	refusal to stop usage
T121	Observation 2405 2414	inability
*	OR T121 T120
T122	Temporal 2319 2328	currently
T123	Scope 2336 2354	folate, B12, or B6
R43	Has_temporal Arg1:T123 Arg2:T122	
T124	Drug 2464 2486	folic acid supplements
T125	Multiplier 2447 2460	Regular usage
T126	Drug 2490 2521	compounds containing folic acid
T127	Temporal 2522 2542	in the past 3 months
*	OR T124 T126
T128	Scope 2464 2521	folic acid supplements or compounds containing folic acid
T129	Scope 2447 2460;2522 2542	Regular usage in the past 3 months
*	OR T125 T127
R44	Has_scope Arg1:T128 Arg2:T129	
T130	Observation 2548 2581	Participation in a clinical trial
T131	Drug 2588 2648	drug that has not yet been officially approved for marketing
T132	Temporal 2649 2690	within one month prior to the first visit
R45	AND Arg1:T130 Arg2:T131	
R46	Has_temporal Arg1:T130 Arg2:T132	
T133	Reference_point 2675 2690	the first visit
R47	Has_index Arg1:T132 Arg2:T133	
